The Impact of Covid-19 Pandemic on Hidradenitis Suppurativa Patients: a Cross-Sectional Study From Tertiary Referral Hospital
Keywords:
Covid-19, hidradenitis supurativa, treatmentAbstract
Introduction: Hidradenitis suppurativa (HS) is a chronic, disabling skin disorder which is characterized by recurrent attacks of nodule, abscess, sinus tract formation which eventually leads to significant scarring. Oral/topical antibiotics, oral retinoids and TNF-alpha inhibitors are used to control disease activity and improve symptoms.
Objective: In the present study, we aimed to determine the prevalance of COVID-19 real-time polymerase chain reaction (RT-PCR) positivity and Covid-19 related symptoms in relation to the age, gender, body mass index (BMI), disease duration, accompanying systemic diseases, treatment used for HS, treatment duration and smoking.
Methods: We conducted a comparative, cross-sectional study of 178 patients diagnosed with HS in a referral hospital. Age, gender, smoking status, BMI, treatment modalities used for HS, the presence of COVID-19 related symptoms, history of close contact to a person with COVID-19 and COVID-19 RT-PCR results were determined by a telephone questionnaire and checked from medical data records.
Results: Sixty-three patients were female, whereas 115 patients were male. During Covid-19 pandemic, 94 out of 178 patients had Covid-19 related symptoms; Covid-19 RT-PCR test was performed in 109 (61.2%) patients. Thirty (27.5%) cases tested positive for Covid-19 whereas 79 (72.5%) tested negative.
Conclusions: Patients having Covid-19 related symptoms were shown to have statistically significantly higher mean age compared to the ones who did not have any symptoms (p=0.031). No statistically significant relationship was found Covid-19 RT-PCR positivity and the type of treatment administered for HS when categorized as TNF-alpha inhibitor, oral retinoid, topical antibiotic and oral antibiotic group (p>0.05).
References
Lee EY, Alhusayen R, Lansang P, Shear N, Yeung J. What is hidradenitis suppurativa? Can Fam Physician 2017;63:114-20.
Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 2021;35:50-61.
Ovadja ZN, Schuit MM, van der Horst C, Lapid O. Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa. Br J Dermatol 2019;181:344-349.
Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009;60:539-61; quiz 62-63.
Pescitelli L, Ricceri F, Prignano F. Hidradenitis suppurativa and associated diseases. G Ital Dermatol Venereol 2018;153:8-17.
Kirby JS, Butt M, Esmann S, Jemec GBE. Association of Resilience With Depression and Health-Related Quality of Life for Patients With Hidradenitis Suppurativa. JAMA Dermatol 2017;153:1263-1269.
Tchero H, Herlin C, Bekara F, Fluieraru S, Teot L. Hidradenitis Suppurativa: A Systematic Review and Meta-analysis of Therapeutic Interventions. Indian J Dermatol Venereol Leprol 2019;85:248-257.
Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015;29:619-644.
Lowe MM, Naik HB, Clancy S, et al. Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-alpha therapy. JCI Insight 2020;5:e139932.
Yim RM, Singh I, Armstrong AW. Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. Dermatol Online J 2020;26:13030/qt0j5150df.
Giamarellos-Bourboulis EJ, Bettoli V, Jemec GBE, et al. Anti-COVID-19 measurements for hidradenitis suppurativa patients. Exp Dermatol 2021;30 Suppl 1:18-22.
Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol 2020;183:999-1010.
Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013;133:97-103.
Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 2015;173:1546-1549.
Miller IM, McAndrew RJ, Hamzavi I. Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa. Dermatol Clin 2016;34:7-16.
Yuan JT, Naik HB. Complications of hidradenitis suppurativa. Semin Cutan Med Surg 2017;36:79-85.
Agrawal A, Sharma YK. Errata: Review article: Hidradenitis suppurativa: A systematic review and meta-analysis of therapeutic interventions. Indian J Dermatol Venereol Leprol 2019;85:617.
Jones ME, Kohn AH, Pourali SP, et al. The Use of Biologics During the COVID-19 Pandemic. Dermatol Clin 2021;39:545-553.
Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol 2020;20:271-272.
Kimball AB, Okun MM, Williams DA, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 2016;375:422-434.
Marasca C, Ruggiero A, Megna M, Annunziata MC, Fabbrocini G. Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. J Dermatolog Treat 2020 May 25:1. doi: 10.1080/09546634.2020.1769828. Epub ahead of print.
Molinelli E, Diotallevi F, Simonetti O, et al. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy. Dermatol Ther 2020;33:e14256.
Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: A review of the literature. Int J Womens Dermatol 2019;5:330-334.
Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020;81:e16-e25.
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;323:1061-1069.
Lowe KE, Zein J, Hatipoglu U, Attaway A. Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. JAMA Intern Med 2021;181:709-711.
Kwok S, Adam S, Ho JH, et al. Obesity: A critical risk factor in the COVID-19 pandemic. Clin Obes 2020;10:e12403.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Ecem Bostan, Adam Jarbou, Aysen Karaduman, Duygu Gulseren, Neslihan Akdogan, Basak Yalici-armagan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
